Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-03

Study Completion Date

2022-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a preliminary trial of a Hepatitis B vaccine (Heplisav-B) in medically immunosuppressed patients. The purpose of this study is to test the ability of Heplisav-B to produce high levels of antibody that neutralize the virus and prevent hepatitis B from coming back. Another important purpose is to test the safety of this vaccine in patients taking immune suppressive medicines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

NCT04843852

Hepatitis B Chronic Hepatitis B

RECRUITING PHASE1

A Study of the Immune Response to Heplisav in Healthy Older Adults

NCT01999699

Hepatitis B

COMPLETED PHASE1

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

NCT00511095

Hepatitis B

COMPLETED PHASE2

Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders

NCT05791851

HIV Infections Hepatitis B Vaccine Response Impaired

COMPLETED

Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine

NCT00435812

Hepatitis B

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label exploratory study of the immunologic efficacy and safety of an FDA-approved Hepatitis B vaccine called Heplisav-B. It will be used in patients treated with long term immunosuppressive drug therapy. The patients will be given two doses of Heplisav-B, the first delivered at the baseline visit and the second at week 4. Antibody levels against the Hepatitis B virus will be measured at baseline and at weeks 4, 8, 12, 24 and 60. The proportion of those patients with protective antibody levels will be compared with non-immune compromised patients receiving the same dosing schedule. Patients who fail to demonstrate protective levels of antibodies at week 8 will be given a third booster dose at week 12, and all patients will be followed to week 60.

This research is being done because current alternative hepatitis B vaccines produce lower levels of antibody to hepatitis B, and the level of antibody can be important in the prevention of the virus coming back. However, administration of Heplisav-B has been associated with higher levels of protective antibody in healthy individuals, people with diabetes, and people with kidney disease. It is hoped that the same beneficial effect of higher antibody level will also occur in patients who take an immune suppressing medicine to treat underlying inflammatory disorder (either arthritis, colitis, or chronic skin inflammation), chemotherapy for cancer, or anti-rejection therapy for liver transplantation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

A total of 18 patients will be entered into the study including 3 evenly sized groups of 6 as follows:

* Group A patients on tumor necrosis factor alpha or interleukin inhibitor therapy for underlying chronic inflammatory disorders
* Group B patients on chemotherapy for solid organ malignancy
* Group C patients are either recipients of livers from anti-HBc positive donors or are patients transplanted for chronic hepatitis B infection without recurrent hepatitis B at the time of enrollment

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

N/A. Investigator and patient will know that the patient received the Heplisav-B vaccine.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heplisav-B Vaccine Recipient

There will be a single group of 18 immune compromised patients who will receive the Heplisav-B vaccine.

Group Type EXPERIMENTAL

Heplisav-B

Intervention Type BIOLOGICAL

This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Heplisav-B

This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older and agree to adhere to study requirements
* Must be willing to provide informed consent
* Serologic profile consistent with resolved hepatitis B (HBsAg negative but anti-HBc positive)
* Must meet one of the following requirements: Recipient of anti-HBc positive liver (Group C), Chronic inflammatory disease requiring TNF or interleukin inhibitor therapy (Group A), Solid organ malignancy that requires systemic cancer chemotherapy (Group B), or Post liver transplant for chronic HBV infection (Group C).
* Recipient of immunosuppressive drug medication as described above

Exclusion Criteria

* HBsAg positivity
* Anti-HBs level \> 20 mIU/mL at baseline
* HIV infection
* HCV infection
* Prior hepatitis B vaccination
* Received hepatitis B immune globulin during the past 4 months
* Hematologic malignancy
* Hepatocellular carcinoma
* Active alcohol use \> 20 grams daily
* Unstable underlying inflammatory disorder
* Pregnancy or breast feeding
* History of severe depression or other severe psychiatric disorder
* Received liver transplant \< 3 years earlier
* Transplant rejection within the past year
* Unstable or poorly responsive inflammatory disorders
* Patients who have an unreasonable risk of complications
* Anticipated life expectancy less than one year

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No